Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 7078669

Periaqueductal gray matter involvement in the muscimol-induced decrease of morphine antinociception.

F Zambotti·N Zonta·M Parenti·R Tommasi·L Vicentini·F Conci·P Mantegazza
View original source ↗Export metadata ↓

Abstract

Microinjections of muscimol, a GABA receptor agonist, into the periaqueductal gray matter (PAG) counter-acted the antinociceptive effect of morphine in rats, as measured by the "tail-flick" method. Muscimol's effect was partially reversed by bicuculline.

Explore related subjects

AnalgesiaAnimalsCerebral AqueductMaleMorphineMuscimolOxazolesRatsRats, Inbred StrainsJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

F Zambotti, N Zonta, M Parenti, R Tommasi, L Vicentini, F Conci, P Mantegazza. 1982. Periaqueductal gray matter involvement in the muscimol-induced decrease of morphine antinociception.. https://doi.org/10.1007/bf00501180

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2005

Systemic administration of propentofylline does not attenuate morphine tolerance in non-injured rodents.

Propentofylline is a phosphodiesterase inhibitor that has been shown to attenuate the onset of morphine tolerance when administered intrathecally to rats. The present studies examined whether systemic administration could be effective in attenuating morphine tolerance in non-injured rodents using a similar dosing paradigm. Propentofylline at 10, 30, or 50 mg/kg, administered intraperitoneally once daily for 5 days, was unable to attenuate morphine tolerance established by twice daily administration of 10 mg/kg morphine. These results suggest that direct delivery of propentofylline to the central nervous system (CNS) may be required in order to attenuate morphine tolerance.

Analgesia↗
PubMed2005

An endocannabinoid mechanism for stress-induced analgesia.

Acute stress suppresses pain by activating brain pathways that engage opioid or non-opioid mechanisms. Here we show that an opioid-independent form of this phenomenon, termed stress-induced analgesia, is mediated by the release of endogenous marijuana-like (cannabinoid) compounds in the brain. Blockade of cannabinoid CB(1) receptors in the periaqueductal grey matter of the midbrain prevents non-opioid stress-induced analgesia. In this region, stress elicits the rapid formation of two endogenous cannabinoids, the lipids 2-arachidonoylglycerol (2-AG) and anandamide. A newly developed inhibitor of the 2-AG-deactivating enzyme, monoacylglycerol lipase, selectively increases 2-AG concentrations and, when injected into the periaqueductal grey matter, enhances stress-induced analgesia in a CB1-dependent manner. Inhibitors of the anandamide-deactivating enzyme fatty-acid amide hydrolase, which selectively elevate anandamide concentrations, exert similar effects. Our results indicate that the coordinated release of 2-AG and anandamide in the periaqueductal grey matter might mediate opioid-independent stress-induced analgesia. These studies also identify monoacylglycerol lipase as a previously unrecognized therapeutic target.

Analgesia↗